This half-day interactive forum will gather business and legal thought leaders involved in groundbreaking technologies such as engineered CAR-T (chimeric antigen receptor T cells) and iPSC (induced pluripotent stem cells) to address key challenges in realizing the promises of regenerative medicine and cell therapy.
Gabor Garai, Partner, Private Equity & Venture Capital Practice, Foley & Lardner LLP
Martin F. Heidecker, PhD, MBA, Managing Director, Boehringer Ingelheim Venture Fund USA Inc.
Paul Holzer, Founder and Chief Executive Officer, XenoTherapeutics Inc.
Stephen B. Maebius, Partner, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP
David L. Rosen, Partner, FDA Regulatory Practice, Foley & Lardner LLP
Kristel Schorr, Partner, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP
Debra Aub Webster, PhD, Principal Scientist, Cardinal Health Regulatory Sciences
There is no fee to attend this event, but advance registration is required. Please click here to register.